La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Ipsen Gestion

Gestion contrôle des critères 4/4

Le PDG Ipsen's est David Loew, nommé en Jul2020, a un mandat de 4.08 ans. La rémunération annuelle totale est € 4.36M, composée du salaire de 22.6% et des bonus 77.4%, y compris les actions et options de la société. détient directement 0.061% des actions de la société, d'une valeur de $ 5.98M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 5.3 ans et 10.7 ans.

Informations clés

David Loew

Directeur général

€4.4m

Rémunération totale

Pourcentage du salaire du PDG	22.6%
Durée du mandat du directeur général	4.2yrs
Propriété du PDG	0.06%
Durée moyenne d'occupation des postes de direction	5.3yrs
Durée moyenne du mandat des membres du conseil d'administration	10.8yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de David Loew a-t-elle évolué par rapport aux bénéfices de Ipsen?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	€664m
Mar 31 2024	n/a	n/a	€641m
Dec 31 2023	€4m	€988k	€617m
Jun 30 2023	n/a	n/a	€406m
Mar 31 2023	n/a	n/a	€500m
Dec 31 2022	€4m	€950k	€593m
Sep 30 2022	n/a	n/a	€656m
Jun 30 2022	n/a	n/a	€719m
Mar 31 2022	n/a	n/a	€675m
Dec 31 2021	€5m	€950k	€631m
Sep 30 2021	n/a	n/a	€626m
Jun 30 2021	n/a	n/a	€622m
Mar 31 2021	n/a	n/a	€585m
Dec 31 2020	€5m	€475k	€548m

Rémunération vs marché: La rémunération totale de David ($USD 4.84M ) est inférieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 13.21M ).

Rémunération et revenus: La rémunération de David a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

David Loew (57 yo)

4.2yrs

Titularisation

€4,361,753

Compensation

Mr. David Loew has been the Chief Executive Officer & MD of Ipsen S.A. since July 1, 2020, and serves as its Director since May 28, 2020. Mr. Loew served as an Executive Vice President of Sanofi Pasteur at...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
David Loew	MD, CEO & Director	4.2yrs	€4.36m	0.061% € 6.3m
Aymeric Le Chatelier	Executive VP & CFO	9.8yrs	€1.02m	pas de données
Aidan Murphy	Executive VP and Head of Technical Operations	6.7yrs	pas de données	pas de données
Craig Marks	Vice-President of Investor Relations	no data	pas de données	pas de données
Francois Garnier	Executive VP of Legal Affairs	9.8yrs	pas de données	pas de données
Regis Mulot	Executive VP & Chief Human Resources Officer	6.5yrs	pas de données	pas de données
Dominique Bery	Head of Nordics & Baltics	7.4yrs	pas de données	pas de données
Bartosz Bednarz	Executive VP and Head of Global Product & Portfolio Strategy	4yrs	pas de données	pas de données
Philippe Lopes-Fernandes	Executive VP & Chief Business Officer	3.9yrs	pas de données	pas de données
James Levine	President of Fondation Ipsen	no data	pas de données	pas de données
Mari Scheiffele	Executive VP & President of International	2.8yrs	pas de données	pas de données
Catherine Abi-Habib	Executive VP and Head of Strategy & Transformation	2.5yrs	pas de données	pas de données

5.3yrs

Durée moyenne de l'emploi

57.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de IPSE.Y est chevronnée et expérimentée (ancienneté moyenne 5.3 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
David Loew	MD, CEO & Director	4.3yrs	€4.36m	0.061% € 6.3m
Marc M. de Garidel	Non-Executive Chairman	13.8yrs	€600.00k	0.17% € 17.2m
Margaret Liu	Independent Director	7.3yrs	€130.00k	0.00083% € 85.4k
Michèle Ollier	Director	9.3yrs	€65.00k	0.00061% € 62.7k
Karen Witts	Independent Director	2.7yrs	€115.00k	0.00061% € 62.7k
Antoine Flochel	Vice Chairman	19.1yrs	€165.00k	0.0036% € 373.3k
Henri Beaufour	Director	19.1yrs	€36.00k	0% € 0
Anne Beaufour	Director	19.1yrs	€45.00k	26.41% € 2.7b
Carol Xueref	Director	12.3yrs	€115.00k	0.00061% € 62.7k
Philippe Bonhomme	Director	12.7yrs	€95.00k	0% € 0
Piet Wigerinck	Independent Director	6.3yrs	€78.00k	0.00082% € 84.3k
Laetitia Ducroquet	Employees Representative Director	3.8yrs	pas de données	0.0010% € 102.8k

10.8yrs

Durée moyenne de l'emploi

60.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration IPSE.Y sont chevronnés et expérimentés (durée moyenne d'administration 10.7 ans).

Ipsen Gestion

Gestion contrôle des critères 4/4

Informations clés

Mises à jour récentes de la gestion

Ipsen Announces Executive Changes

Ipsen Appoints Catherine Abi-Habib as EVP Strategy, Transformation, and Digital

Ipsen Appoints Gwenan White as Executive Vice President Communications and Public Affairs

Ipsen Appoints Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer

Recent updates

Ipsen Provides Update on CONTACT-02 Phase III Trial in Metastatic Castration-Resistant Prostate Cancer Following Final Overall Survival Analysis

Ipsen Receives CHMPPositive Opinions for Iqirvo® (Elafibranor) in Primary Biliary Cholangitis and Kayfanda® (Odevixibat) in Alagille Syndrome, Two Rare Cholestatic Liver Diseases

Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2024

Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis

Ipsen S.A. Approves Dividend, Payable on 3 June 2024

Ipsen Announces Executive Changes

Ipsen’s Onivyde Regimen, Potential New Standard-Of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA

Ipsen Announces Latest Phase III Trial Data Investigating Cabometyx®? in Combination with Immunotherapy to Be Present at ASCO Gu 2024

Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC

Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial

Ipsen S.A. to Report Q4, 2023 Results on Feb 08, 2024

Ipsen S.A. to Report First Half, 2024 Results on Jul 24, 2024

IRLAB Therapeutics AB Announces Further Information on Results from Mesdopetam’s Clinical Phase IIb Study in Parkinson’s Disease Levodopa-Induced Dyskinesias and Phase III Preparatory Phase I Studies Performed by Ipsen

Ipsen Provides Update on E.U. Marketing Authorization Application for Bylvay for Cholestatic Pruritus in Patients with Alagille Syndrome

Ipsen Announces European Commission Decision on Palovarotene for the Treatment of FOP

Ipsen and GENFIT Announces Positive Results from Phase III ELATIVE Trial of Elafibranor in Patients with Primary Biliary Cholangitis, A Rare Cholestatic Liver Disease

Ipsen Announces U.S. FDA Submission Acceptance of Its Supplemental New Drug Application for Onivyde Regimen in First-Line Metastatic Pancreatic Ductal Adenocarcinoma

Ipsen Announces U.S. FDA Approves Bylvay® for Patients Living with Cholestatic Pruritus Due to Alagille Syndrome

Ipsen to Present New Data

Ipsen S.A. Approves Dividend, Payable on 6 June 2023

Ipsen S.A. Proposes Final Dividend for the Financial Year 2022, Payable on June 6, 2023

Ipsen S.A. Provides Earnings Guidance for the Full Year 2023

Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U

Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde(R) Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma At Asco GI

Ipsen S.A. (ENXTPA:IPN) entered into a definitive merger agreement to acquire Albireo Pharma, Inc. (NasdaqCM:ALBO) for approximately $870 million.

Ipsen S.A. Provides Update on Phase III CONTACT-01 Trial Evaluating Cabozantinib

Ipsen Announces Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Ipsen S.A. Provides Earnings Guidance for the Financial Year 2023

Ipsen S.A. to Report Fiscal Year 2022 Results on Feb 09, 2023

Ipsen S.A. to Report Q2, 2023 Results on Jul 27, 2023

Ipsen S.A. to Report Q3, 2022 Results on Oct 26, 2022

Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde in Second-Line Monotherapy for Small Cell Lung Cancer

Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2022

Ipsen Announces U.S. FDA Priority Review for Palovarotene New Drug Application in Patients with Fibrodysplasia Ossificans Progressiva Following Resubmission

Ipsen Announces at ASCO 2022 New Cabometyx Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types

Ipsen S.A. Approves Dividend, Payable on 2 June 2022

Ipsen S.A. Approves Dividend, Payable on 2 June 2022

Ipsen S.A. Proposes Dividend for the Financial Year 2021, payable on 2 June 2022

Exelixis, Inc. Partner Ipsen Receives European Commission Approval for Cabometyx® (Cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Ipsen S.A. Provides Sales Guidance for the Year 2022

Ipsen Appoints Catherine Abi-Habib as EVP Strategy, Transformation, and Digital

Ipsen S.A. Announces Two-Year Follow-Up Results from Analyses of the Phase III Checkmate -9ER Trial

Ipsen S.A. Proposes Dividend for the Year 2021

Ipsen Announces the Health Canada Approval of Sohonos as the First Treatment for Fibrodysplasia Ossificans Progressiva

Cabometyx® Demonstrates Sustained 78% Reduction in Risk of Disease Progression or Death in People Living With Uncommon Form of Thyroid Cancer

Ipsen Announces Withdrawal of Palovarotene NDA, Confirming Intention to Re-Submit Following Additional Data Analyses

Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021

Ipsen S.A. Confirms U.S. Fda Accepts New Drug Application for Palovarotene as the First Potential Treatment Worldwide for Fibrodysplasia Ossificans Progressiva (Fop)

Ipsen Opts-In to Join Exelixis, Inc With Ongoing Development of Cabometyx® for People Living With a Form of Thyroid Cancer, Based on Promising Interim Results

Ipsen Receives Positive CHMP Opinion Recommending Cabometyx® in Combination with Opdivo® as First-Line Treatment for Patients Living with Advanced Renal Cell Carcinoma

Ipsen Announces New Data from the Phase II CLARINET FORTE Study Which Demonstrated Preservation of Quality of Life When Increasing Dose Frequencies of Somatuline Autogel (lanreotide)

Ipsen S.A. Announces New Data From Pivotal Phase III CheckMate -9ER trial of Cabometyx®

Ipsen to Showcase Commitment to Going Beyond Traditional Outcome Measures for Patients Living with Renal Cell Carcinoma At ASCO GU 2021

Ipsen Appoints Gwenan White as Executive Vice President Communications and Public Affairs

Ipsen Announces New Analyses of Pivotal Phase III Trial Data Highlight Long Duration of Response for Dysport (Abobotulinumtoxina) in Five Therapeutic Indications

Ipsen S.A. to Report Fiscal Year 2020 Results on Feb 11, 2021

Ipsen to Present 12 Abstracts at the 11th World Congress for Neurorehabilitation (WCNR) Virtual Congress Taking Place Jointly With the 35th Congress of the French Society of Physical and Rehabilitation Medicine (SOFMER)1-13

Ipsen Appoints Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer

Ipsen Announces First Presentation of Results from the Pivotal Phase III CheckMate -9ER Trial

Ipsen Announces the Release of First Efficacy and Safety Data from the Clarinet Forte Study

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen